Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
What do you make of it?
Read the story
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.